AbbVie Inc. $ABBV Holdings Lifted by Capital Advisors Inc. OK

Capital Advisors Inc. OK increased its holdings in AbbVie Inc. (NYSE:ABBV) by 10.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 381,648 shares of the company’s stock after acquiring an additional 34,548 shares during the period. AbbVie comprises about 1.5% of Capital Advisors Inc. OK’s holdings, making the stock its 14th largest holding. Capital Advisors Inc. OK’s holdings in AbbVie were worth $88,367,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Conning Inc. grew its position in AbbVie by 7.1% in the second quarter. Conning Inc. now owns 191,023 shares of the company’s stock worth $35,458,000 after acquiring an additional 12,690 shares in the last quarter. Diversified Trust Co lifted its stake in shares of AbbVie by 23.6% in the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock valued at $13,215,000 after purchasing an additional 10,891 shares during the last quarter. Dohj LLC boosted its holdings in AbbVie by 41.8% in the second quarter. Dohj LLC now owns 4,529 shares of the company’s stock worth $802,000 after purchasing an additional 1,335 shares in the last quarter. Permanent Capital Management LP acquired a new position in AbbVie during the third quarter worth $720,000. Finally, First Hawaiian Bank increased its position in AbbVie by 0.8% during the second quarter. First Hawaiian Bank now owns 7,556 shares of the company’s stock worth $1,403,000 after buying an additional 60 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ABBV has been the subject of a number of analyst reports. Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Berenberg Bank upgraded AbbVie from a “hold” rating to a “buy” rating and increased their price target for the company from $170.00 to $270.00 in a report on Wednesday, September 17th. Scotiabank initiated coverage on shares of AbbVie in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price target on the stock. Raymond James Financial set a $256.00 price objective on shares of AbbVie in a report on Monday, November 3rd. Finally, JPMorgan Chase & Co. raised their target price on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Three research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $245.84.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Signed a licensing/option deal with Zelgen around a T‑cell engager worth up to $1.1B, strengthening AbbVie’s oncology pipeline and potential future revenue streams. New year sees Abbvie, Zelgen in $1.1B T-cell engager deal
• Positive Sentiment: Zelgen Pharma confirmed a licensing option agreement with AbbVie, reiterating the near-term deal structure that adds option value to AbbVie’s immuno‑oncology portfolio. Zelgen Pharma inks licensing option agreement with AbbVie
• Positive Sentiment: AbbVie (and peers) are acquiring/licensing clinical‑stage cancer assets in multiple deals, accelerating near‑term pipeline growth without full internal development cost. AbbVie, Gilead gift themselves clinical-stage cancer drugs via licensing deals
• Positive Sentiment: Neuroscience franchise (Botox, Vraylar, migraine drugs) now contributes >17% of revenue and is fueling double‑digit sales growth, supporting AbbVie’s top line even as other areas reset. Here’s How AbbVie’s Neuroscience Portfolio Is Aiding Top-line Growth
• Positive Sentiment: Partner performance (Ironwood’s beat tied to AbbVie‑partnered Linzess) highlights durable royalties/partner cash flow from legacy assets. Ironwood beats on 2026 outlook thanks to AbbVie-partnered Linzess
• Positive Sentiment: Wall Street Zen changed coverage to a Buy, an analyst upgrade that can support near‑term investor demand. AbbVie (NYSE:ABBV) Cut to Buy at Wall Street Zen
• Neutral Sentiment: Analysts and previews expect AbbVie’s upcoming Q4 report to show double‑digit EPS growth; the print will be a key near‑term catalyst. What to Expect From AbbVie’s Next Quarterly Earnings Report
• Neutral Sentiment: Additional earnings previews reiterate expectations for strong bottom‑line growth, making the earnings release the primary short‑term focus. What to Expect From AbbVie’s Next Quarterly Earnings Report
• Neutral Sentiment: Balanced analyst commentary: some see an attractive setup for 2026 given growth and dividends, but note company risks. AbbVie: Solid Growth, Some Risks, And An Attractive Setup In 2026
• Negative Sentiment: Valuation concerns: analysts note recent rally but argue ABBV may not be a bargain given a high P/E and limited margin for upside absent strong surprises. AbbVie’s Rally Looks Convincing — But The Stock Is Not A Bargain
• Negative Sentiment: Macro/rate risk: commentary to dividend investors warns that shifting Treasury issuance and shorter maturities make dividend stocks more sensitive to Fed policy — a potential headwind for high‑yield pharma names. My Most Important Warning To Dividend Investors For 2026

AbbVie Trading Up 0.3%

Shares of AbbVie stock opened at $229.26 on Friday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The company’s fifty day simple moving average is $226.69 and its 200-day simple moving average is $213.94. The company has a market cap of $405.19 billion, a price-to-earnings ratio of 173.68, a PEG ratio of 0.96 and a beta of 0.36.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a $1.73 dividend. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is 496.97%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.